Federal Register of Legislation - Australian Government

Primary content

PB 75 of 2021 Other as made
This instrument amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015) to add, delete and alter listed pharmaceutical items and associated periods and circumstances.
Administered by: Health
Registered 31 Jul 2021
Tabling HistoryDate
Tabled HR03-Aug-2021
Tabled Senate03-Aug-2021
Date of repeal 19 Oct 2021
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 75 of 2021

 

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021
(No. 7)

 

National Health Act 1953

___________________________________________________________________________

 

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

 

Dated         27 July 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NIKOLAI TSYGANOV

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health


 

___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 7).

(2)          This Instrument may also be cited as PB 75 of 2021.

2          Commencement

This Instrument commences on 1 August 2021.

3          Amendment of National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

                             

                             

 

 

 

 

 

 

 

 

 

 

 

 

 

                             


Schedule 1       Amendments

[1]        Schedule 1, after entry for Alendronic acid with colecalciferol and calcium

insert:

Alirocumab

Injection 75 mg in 1 mL single use pre-filled pen

20

2

5

 

 

Injection 150 mg in 1 mL single use pre-filled pen

20

2

5

 

[2]        Schedule 1, entry for Exenatide

omit:

 

Injection (modified release) 2 mg single dose pre‑filled pen

20

4

5

 

[3]        Schedule 1, after entry for Fosinopril with hydrochlorothiazide

insert:

Fremanezumab

Solution for injection 225 mg in 1.5 mL single dose pre-filled syringe

20

1

2

 

 

 

20

1

5

 

[4]        Schedule 1, after entry for Riluzole

insert:

Risdiplam

Powder for oral solution 750 micrograms per mL, 80 mL

20

1

0

 

 

 

20

1

5